Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity by DeStefanis, Rebecca A., Kratz, Jeremy D., Olson, Autumn M., Sunil, Aishwarya, DeZeeuw, Alyssa K., Gillette, Amani A., Sha, Gioia C., Johnson, Katherine A., Pasch, Cheri A., Clipson, Linda, Skala, Melissa C., Deming, Dustin A.

Get full text

Carboplatin and Paclitaxel Chemoradiation for Localized Anal Cancer in Patients Not Eligible for Mitomycin and 5-Fluorouracil by DeZeeuw, Alyssa K, Bassetti, Michael F, Carchman, Evie H, Heise, Charles P, Hayden, Dana, Lawson, Elise H, Sanger, Cristina B, King, Ray, LoConte, Noelle K, Lubner, Sam J, Kratz, Jeremy D, Deming, Dustin A

Get full text

Abstract 3048: Murine-derived colorectal cancer organoid culture high-throughput drug screening to identify novel combinations targeting PIK3CA mutant cancers by DeZeeuw, Alyssa K., DeStefanis, Rebecca A., Sha, Gioia, Pasch, Cheri A., Clipson, Linda, Deming, Dustin A.

Get full text

Abstract 2969: Impact of baseline culture condition on the growth and treatment response of mouse derived cancer organoids by Olson, Autumn, DeStefanis, Rebecca A., DeZeeuw, Alyssa, Anderson, Samantha, Sha, Gioia, Kratz, Jeremy, Pasch, Cheri, Clipson, Linda, Deming, Dustin A.

Get full text

Abstract 1944: Navitoclax enhances the efficacy of copanlisib predominantly through inhibition of BCLxL in PIK3CA mutant colorectal cancer by DeStefanis, Rebecca Anna, DeZeeuw, Alyssa, Sha, Gioia, Olson, Autumn, Anderson, Samantha J., Babiarz, Christopher P., Pasch, Cheri A., Clipson, Linda, Deming, Dustin A.

Get full text

Abstract 75: BCL-xL inhibition enhances therapeutic response of MTORC1/2 inhibition and induction of apoptosis in PIK3CA mutant colorectal cancer by DeStefanis, Rebecca A., DeZeeuw, Alyssa, Sha, Gioia, Payne, Susan N., Babiarz, Christopher P., Miller, Devon, Korkos, Demetra K., Pasch, Cheri A., Clipson, Linda, Matkowskyj, Kristina, Deming, Dustin A.

Get full text

Abstract 1128: MTORC1/2 and HDAC1/2 inhibition promote tumor response through inhibition of MYC by DeStefanis, Rebecca A., Olson, Autumn M., DeZeeuw, Alyssa K., Payne, Susan N., Pasch, Cheri A., Clipson, Linda, Deming, Dustin A.

Get full text

Abstract 3721: MTORC1/2 and HDAC1/2 inhibition as therapy for colorectal cancer with PIK3CA mutation by Olson, Autumn M., DeStefanis, Rebecca A., DeZeeuw, Alyssa K., Payne, Susan N., Pasch, Cheri A., Clipson, Linda, Deming, Dustin A.

Get full text

Abstract 2673: Combined inhibition of PI3K and HDAC1/2 as a novel treatment strategy for RAS/RAF wildtype colorectal cancer in a patient derived organoid model by DeZeeuw, Alyssa K., DeStefanis, Rebecca A., Payne, Susan N., Olson, Autumn M., Pasch, Cheri A., Clipson, Linda, Deming, Dustin A.

Get full text

Abstract B27: MTORC1/2 inhibition as a treatment strategy for PIK3CA mutant colorectal cancer by DeStefanis, Rebecca A., Payne, Susan N., Miller, Devon, Pasch, Cheri A., Babiarz, Christopher, DeZeeuw, Alyssa, Fricke, Stephanie L., Sprackling, Carley, Yueh, Alexander E., Korkos, Demetra P., Van De Hey, Dana R., Sha, Gioia, Greane, Aurora, Kratz, Jeremy D., Clipson, Linda, Matkowskyj, Kristina A., Newton, Michael A., Deming, Dustin A.

Get full text

Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation by Pasch, Cheri A, Favreau, Peter F, Yueh, Alexander E, Babiarz, Christopher P, Gillette, Amani A, Sharick, Joe T, Karim, Mohammad Rezaul, Nickel, Kwangok P, DeZeeuw, Alyssa K, Sprackling, Carley M, Emmerich, Philip B, DeStefanis, Rebecca A, Pitera, Rosabella T, Payne, Susan N, Korkos, Demetra P, Clipson, Linda, Walsh, Christine M, Miller, Devon, Carchman, Evie H, Burkard, Mark E, Lemmon, Kayla K, Matkowskyj, Kristina A, Newton, Michael A, Ong, Irene M, Bassetti, Michael F, Kimple, Randall J, Skala, Melissa C, Deming, Dustin A

Get full text